ANCON appoints new Group CEO: Dr Linda Pomeroy
Dr Pomeroy will drive the leading biotech company into its next phase of growth
ANCON Technologies, the leading diagnostics and chemical detection firm, today announced the appointment of Dr Linda Pomeroy as the new group CEO, taking over from Dr Robert Muir who will remain part of the management team before transitioning to a role as a Non-Executive Director.
Dr Pomeroy joins the company after two years as Global Insights Director at AstraZeneca, bringing with her a wealth of experience in big pharma, start-ups, and life sciences.
With the SMEs’ current capabilities proving revolutionary in the challenges surrounding early detection for COVID-19, ANCON’s growth strategy over the coming five years will include commercialising the technology, developing a strong pipeline and building a sustainable company, for which Dr Pomeroy’s extensive experience will prove critical.
Wesley Baker – CEO of ANCON Medical, said:
“We are hugely excited to welcome Linda to the ANCON team in what is a very exciting time for the business. She will be a fantastic addition with both the energy and experience to drive ANCON forward and help us to reach our potential.”
Dr Linda Pomeroy – new GROUP CEO of ANCON Technologies, said:
“ANCON has a huge opportunity not only to grow but also to make an impact on the MedTech market in the coming years. In previous roles I have helped firms grow through innovation and investment and intend to continue that with ANCON. As a scientist with an academic and professional background in biology and life sciences, I am excited about the firm’s technologies and look forward to bringing them to market in the coming months and years.”